Cargando…
Impact of adjuvant imatinib on bone and muscle density in patients with resected gastrointestinal stromal tumors
Adjuvant treatment with Imatinib is the standard of care for high-risk resected GISTs. Imatinib is known to have an impact on bone mineral density in patients affected by chronic myeloid leukemia, however this effect has never been investigated in GISTs. We retrospectively evaluated, on CT scans, th...
Autores principales: | Fulgenzi, Claudia Angela Maria, Napolitano, Andrea, Faiella, Eliodoro, Messina, Laura, Castiello, Gennaro, Paternostro, Flavia, Silletta, Marianna, Pantano, Francesco, Tonini, Giuseppe, Santini, Daniele, Vincenzi, Bruno |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931443/ https://www.ncbi.nlm.nih.gov/pubmed/35309238 http://dx.doi.org/10.1016/j.jbo.2022.100422 |
Ejemplares similares
-
New frontiers in the medical management of gastrointestinal stromal tumours
por: Mazzocca, Alessandro, et al.
Publicado: (2019) -
Imatinib rechallenge in patients with advanced gastrointestinal
stromal tumors following progression with imatinib, sunitinib and
regorafenib
por: Vincenzi, Bruno, et al.
Publicado: (2018) -
Optimizing Adherence to Adjuvant Imatinib in Gastrointestinal Stromal Tumor
por: Tetzlaff, Eric D., et al.
Publicado: (2013) -
Neoadjuvant versus adjuvant imatinib in primary localized gastrointestinal stromal tumor
por: Ling, Jiayu, et al.
Publicado: (2023) -
Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib
por: Joensuu, Heikki, et al.
Publicado: (2014)